Table I.
General Characteristics: Stratified Sample by Uric Acid Quartiles
| Diuretic Users | Non‐Users of Diuretics | |||||||
|---|---|---|---|---|---|---|---|---|
| Parameter | 1st quartile (2.0–4.2 mg/dL) (n=51) | 2nd quartile (4.3–5.0 mg/dL) (n=57) | 3rd quartile (5.1–6.0 mg/dL) (n=59) | 4th quartile (6.1–10.0 mg/dL) (n=79) | 1st quartile (2.0–4.2 mg/dL) (n=40) | 2nd quartile (4.3–5.0 mg/dL) (n=38) | 3rd quartile (5.1–6.0 mg/dL) (n=37) | 4th quartile (6.1–10.0 mg/dL) (n=24) |
| Age, y | 57.3±9.1 | 56.7±8.5 | 58.1±9.4 | 59.4±8.8 | 54.6±11.7 | 58.1±10.8 | 58.5±9.9 | 63.2±9.0b |
| DM, % | 33.3 | 26.3 | 20.3 | 39.2 | 25.0 | 21.1 | 35.1 | 25.0 |
| Menopause, % | 72.5 | 71.9 | 74.6 | 82.3 | 50.0 | 68.4 | 75.7 | 87.5b |
| Smoking, % | 7.8 | 7.0 | 3.4 | 11.4 | 5.0 | 2.6 | 8.1 | 12.5 |
| CVD, % | 2.0 | – | 11.9 | 15.2a | 7.5 | 15.8 | 5.4 | 8.3 |
| ACEI/ARB use, % | 70.6 | 80.7 | 72.9 | 79.7 | 52.5 | 65.8 | 70.3 | 70.8 |
| BMI, kg/m² | 29.0±4.9 | 29.6±5.9 | 31.2±5.2 | 33.1±5.3a | 27.4±5.4 | 28.8±4.9 | 31.3±4.9 | 30.5±4.5a |
| SBP, mm Hg | 138±16 | 136±14 | 139±23 | 138±18 | 137±16 | 140±13 | 139±19 | 140±23 |
| DBP, mm Hg | 84±12 | 85±9 | 86±11 | 86±13 | 86±10 | 85±7 | 85±8 | 82±10 |
| Waist, cm | 91.1±12.4 | 92.5±13.8 | 97.4±11.1 | 101.6±10.0a | 89.0±12.8 | 93.1±10.4 | 98.7±10.9 | 98.5±12.2a |
| HDL‐C, mg/dL | 66.3±17.1 | 61.2±12.1 | 55.8±13.6 | 55.2±14.2a | 64.6±17.6 | 61.0±14.7 | 57.8±11.7 | 56.5±20.9 |
| LDL‐C, mg/dL | 115.5±31.3 | 124.2±32.3 | 122.4±29.6 | 129.0±39.5 | 127.6±39.4 | 139.3±42.2 | 123.6±31.5 | 131.1±43.9 |
| Triglycerides, mg/dL | 129.3±65.8 | 127.0±81.8 | 160.4±79.5 | 178.8±99.2a | 116.5±48.2 | 127.4±54.5 | 147.7±74.0 | 194.1±121.1a |
| Glycemia, mg/dL | 105.1±43.4 | 96.2±35.8 | 98.3±31.5 | 111.7±37.9 | 106.2±59.8 | 97.4±32.7 | 97.8±38.3 | 102.2±35.2 |
| Uric acid, mg/dL | 3.62±0.48 | 4.62±0.21 | 5.57±0.28 | 7.18±0.89 | 3.58±0.57 | 4.7±0.24 | 5.44±0.28 | 6.9±0.83 |
| Creatinine, mg/dL | 0.85±0.1 | 0.94±0.12 | 0.95±0.14 | 1.04±0.27a | 0.86±0.09 | 0.95±0.17 | 0.92±0.18 | 0.95±0.13 |
| Leukocytes, N/mm³ | 5496±1622 | 5998±1762 | 6355±2344 | 6619±2059b | 6095±1900 | 5955±2005 | 6340±2168 | 6473±1762 |
| Albuminuria, μg/min | 16.8±28.8 | 7.8±10.5 | 17.2±47.5 | 45.8±133.3 | 14.2±27.6 | 48.8±237.6 | 53.4±210.3 | 9.0±15.0 |
| eGFR (MDRD), mL/min/1.73 m² | 76.6±11.6 | 68.5±10.3 | 66.4±10.6 | 62.5±15.5a | 74.5±10.7 | 67.8±13.2 | 72.2±17.3 | 65.1±13.6b |
| TG/HDL | 2.21±1.63 | 2.31±2.16 | 3.07±1.83 | 3.61±2.62a | 2.05±1.27 | 2.31±1.35 | 2.72±1.51 | 4.04±3.15a |
| Apo B/apo A‐I | 0.67±0.21 | 0.73±0.2 | 0.74±0.17 | 0.82±0.21a | 0.71±0.27 | 0.75±0.2 | 0.74±0.21 | 0.78±0.19 |
| CRP, mg/dL | 0.41±0.45 | 0.58±0.70 | 0.77±0.73 | 0.84±0.77c | 0.4±0.35 | 0.63±1.15 | 0.57±0.49 | 0.73±0.7 |
| Framingham score | 14.8±3.3 | 14.8±3.5 | 15.2±4.3 | 16.5±3.2b | 13.0±5.2 | 15.3±3.9 | 15.4±3.6 | 17.3±2.9a |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; Apo, apolipoprotein; BMI, body mass index; CRP, C‐reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; MDRD, modification of diet in renal disease; SBP, systolic blood pressure; TG, triglycerides. a P<.01 intragroup. b P<.05 intragroup. c P<.05 intragroup (Kruskal–Wallis test).